TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants must be of non-childbearing potential: postmenopausal for at least 2 years or surgically sterile or otherwise incapable of becoming pregnant~* Female participants, except for postmenopausal women, must have a negative serum pregnancy test at screening~* Participants must agree to comply with contraceptive measures as mentioned in protocol~* Participants must be sero-suitable for respiratory syncytial virus (RSV) within 57 days prior to inoculation~* Participants must be non-smokers for at least one month prior to screening and participants must have a negative cotinine test at screening~Exclusion Criteria:~* Participants with a past history of heart arrhythmias (extrasystoli, tachycardia at rest) or of risk factors for Torsade de Pointes syndrome~* Participants with a history or evidence of abuse of alcohol, barbiturates, amphetamines, recreational or narcotic drug use within the past 3 months, which in the Investigator's opinion would compromise participant's safety and/or compliance with the study procedures~* Participants with current human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection at screening~* Participants with current hepatitis A infection, or hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection (confirmed by HCV antibody) at screening~* Participants with active acute respiratory infection at admission (Study Day -1 or -2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
- Cohort 2 (Type: EXPERIMENTAL): Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
- Cohort 3 (Type: EXPERIMENTAL): Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Criteria:~* Histologically confirmed adenocarcinoma of the prostate~* Clinical stage T1c or T2 (stage II)~* Gleason score of 6 or 7 on initial biopsy~* Prostate-specific antigen (PSA) level less than 10 ng/mL within the past 3 months~* Candidate for and scheduled to undergo prostatectomy~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 70-100%~* Fertile patients must use effective contraception~* No active malignancy at any other site~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to finasteride~* No uncontrolled intercurrent illness including, but not limited to, any of the following: Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia~* No psychiatric illness or social situation that would preclude study compliance~* More than 6 months since prior hormonal agents, including dutasteride or finasteride~* More than 6 months since prior chemotherapy~* More than 1 month since prior participation in another investigational study~* No prior radiotherapy for the primary tumor~* No concurrent dehydroepiandrosterone, phytoestrogen supplements, antiandrogen therapy, dutasteride, or other finasteride~* No concurrent anticoagulation, except for the use of daily acetylsalicylic acid (81 mg to 325 mg)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Finasteride) (Type: EXPERIMENTAL): Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
- Arm II (Placebo) (Type: PLACEBO_COMPARATOR): Placebo once daily for 4-6 weeks, then undergo prostatectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vasopressin, Epinephrine, and Steroids for Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with refractory inhospital cardiac arrest, defined as epinephrine requirement for ventricular fibrillation/tachycardia or asystole/pulseless electrical activity according to guidelines for resuscitation 2005 (5).~Exclusion Criteria:~* Age \< 18 years~* Terminal illness or do-not resuscitate status~* Cardiac arrest due to exsanguination~* Cardiac arrest before hospital admission~* Pre-arrest treatment with intravenous corticosteroids~* Previous enrollment in or exclusion from the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: EXPERIMENTAL): Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
- Control Group (Type: PLACEBO_COMPARATOR): Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60~* Ability to speak English~* Undergoing non-cardiac, non-neurologic surgical procedures; surgery scheduled to last \> 2 hours; due to be admitted to the hospital following surgery~Exclusion Criteria:~* Inmate of a correctional facility~* Scheduled to receive systemic chemotherapy between the time of the two cognitive testing sessions~* Known inability to undergo LPs due to anticoagulant use, severe anxiety, or other clinical contraindication known ahead of time.~* Inappropriate for study inclusion based on the judgement of the principal investigator.~* If a patient undergoes major head trauma that occurs between the times of the two cognitive testing sessions, then they will be withdrawn from the study.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CN-105 (Type: EXPERIMENTAL): Cohort 1: 50 Patients Dose of CN-105: 0.1 mg/kg~Cohort 2: 50 Patients Dose of CN-105: 0.5 mg/kg~Cohort 3: 50 Patients Dose of CN-105: 1 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Cohort 1: 17 Patients receiving placebo~Cohort 2: 17 Patients receiving placebo~Cohort 3: 17 Patients receiving placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects with HAE Type I or II who either have participated in a previous BCX7353 study or, in selected countries, in the opinion of the Investigator are expected to derive benefit from an oral treatment for the prevention of angioedema attacks.~* Access to appropriate medication for treatment of acute attacks~* Acceptable effective contraception~* Written informed consent~Key Exclusion Criteria:~* Pregnancy or breast-feeding~* Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study~* Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study~* Discontinuation of study drug due to a hypersensitivity reaction BCX7353 in a prior study~* Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology~* Unacceptable noncompliance in a previous BCX7353 study (if applicable) as assessed by the Sponsor or Investigator~* Investigational drug exposure, other than BCX7353, within 30 days prior to the screening visit (or baseline if no screening visit)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCX7353 150 mg once daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Acupuncture in the Placental Expulsion Time

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primiparous women between 20 and 35 years old~* Within 37 and 42 weeks of gestation~* Low obstetric risk labor~* With epidural analgesia~Exclusion Criteria:~* Myomatosis~* Coagulation disorders~* Placental alterations (placenta previa or placenta accreta)~* Uterine overdistension (multiple pregnancy, polyhydramnios or fetal macrosomia)~* Previous abortions and subject to curettage evacuator.~* Previous uterine surgeries~* Prolonged labor (more than 11 hours) or too fast labor (less than 2 hours)~* Use of uterine relaxants during childbirth (magnesium sulfate or halogenates anaesthetic drugs)~* People uncapable to give the informed consent

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Acupuncture (Type: EXPERIMENTAL): In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
- Sham acupuncture (Type: SHAM_COMPARATOR): Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probe Based Confocal Laser Endomicroscopy During Thoracoscopy for Pleural Malignancies Diagnosis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Every patient refered for a medical thoracoscopy and willing to participate.~Exclusion Criteria:~* \< 18 ans

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient aged more than 18 years admitted for thoracoscopy (Type: None): Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria~* Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at Baseline~Exclusion Criteria:~* Secondary or primary progressive multiple sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ozanimod 0.5 mg (Type: EXPERIMENTAL): Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
- Ozanimod 1 mg (Type: EXPERIMENTAL): Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Adult patient with sickle cell anemia (SS homozygous, SC heterozygous compound Sbetathal heterozygous)~Exclusion Criteria:~* Heterozygous sickle cell anemia~* Active infection~* Hypersensitivity known or suspected to Prevenar 13® or to Pneumo 23® or to any of the excipients included in the formulation or in the administration system~* Coagulation abnormality indicating against an intramuscular injection (Platelets \<50 000 or TP\<50%)~* Current chemotherapy or radiotherapy, except for using Siklos®/Hydrea® in the context of sickle cell anemia~* Vaccination whatever in the last 2 months before the protocol vaccination, except influenza vaccination (within 30 days)~* Vaccination whatever, provided in the first 2 months following the protocol vaccinations, except influenza vaccination (within the first month following the protocol vaccinations))~* History of pneumococcal vaccination with Pneumo 23® in the previous year~* End-stage renal failure(dialyzed patient, clearance\<10ml/mn)~* HIV infection at baseline~* Pregnancy or breastfeeding (A dosage of betaHCG will be conducted for women in childbearing age),contraception recommendation the first 8 weeks of the test for women in childbearing age~* Participation in a clinical research protocol using a drug within the month prior to inclusion.~* No medical assurance~* Adults under tutelage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCV vaccine following by the PSV vaccine (Type: EXPERIMENTAL): Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
- vaccine Pneumo 23 (Type: ACTIVE_COMPARATOR): Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study With SNF472 in Calciphylaxis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with either newly diagnosed CUA OR recurrent CUA that has been dormant with no skin lesion involvement for at least 90 days from study start (new or recurrent diagnosis must be made within 5 weeks of study start)~2. Patients who signed the written informed consent to participate in this clinical trial (prior to any clinical trial-related procedures being performed), after reading the Patient Information Sheet and Informed Consent Form (ICF), and who had the opportunity to discuss the clinical trial with the Investigator or designee~3. Males or females aged ≥18~4. Patients on maintenance haemodialysis (HD)~5. Patients with at least a minimum level of pain on Visual Analog Scale (VAS) scale or on pain-killers stronger than non-steroidal anti-inflammatory drugs (NSAIDs)~6. Females of child-bearing potential should use a highly effective contraceptive measure throughout the study and have a negative serum pregnancy test at entry. Male patients having sexual relationship in which pregnancy can occur should take adequate contraceptive precautions (wear a condom)~Exclusion Criteria:~1. Body weight above 150 kg~2. BMI \>35 and central(abdominal) ulcers~3. History of bisphosphonate treatment within 12 months before entering into the study~4. Severely ill patients without reasonable expectation of survival for \> 6 months according to the treating physician~5. Patients with scheduled parathyroidectomy during the run-in or study period~6. Female patients who are either intending to get pregnant or are undergoing treatment to get pregnant, as well as breast-feeding females~7. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion~8. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent, or limit the ability of the patient to comply with the Clinical Trial Protocol requirements~9. Patients who, in the opinion of the Investigator, are considered unsuitable for any other reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SNF472 (Type: OTHER): SNF472 for calciphylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60+ years of Age~* Signed an informed consent prior to the start of study~* Non-Feverish, (less than 101.0°F / 38.3°C) on day of vaccination~* Females must be postmenopausal or have a negative pregnancy test~Exclusion Criteria:~* A history of allergic reaction to any vaccine component (including gelatin or neomycin)~* Prior receipt of any varicella or zoster vaccine~* Any live virus vaccine administered within 4 weeks before the start of the study or scheduled during the 42 days after vaccination~* Any inactivated virus vaccine, except for flu vaccine, administered within 7 days before the start of the study or scheduled during the 42 days after vaccination~* Subject is pregnant or breastfeeding~* Participation in an investigational drug or vaccine study within the last 30 days prior to the start of the study or expected during the 42 days after vaccination~* An ongoing illness (including active untreated tuberculosis) that might interfere with or prevent the subject from completion of the study~* Use of immunosuppressive therapy. Subjects taking corticosteroids such as prednisone should be excluded. Excluded immunosuppressive therapies also include chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation~* Known or suspected immune dysfunction that is caused by a medical condition or any other cause. Examples of medical conditions associated with immune dysfunction include congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, or generalized malignancy. Subjects with a history of cancer who are not on active treatment and are not thought to have a weakened immune system at the time of enrollment will be eligible~* Any active use of non-topical antiviral therapy including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, brivudine, and cidofovir

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: vaccine
- 2 (Type: PLACEBO_COMPARATOR): Arm 2: Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete